Vasoactive intestinal peptide inhibits cycloxygenase-2 expression in activated macrophages, microglia, and dendritic cells

Brain, Behavior, and Immunity

Volumn 22, Issue 1, 2008, Pages 35-41

  Gonzalez Rey, Elena ^a   Delgado, Mario ^a  

^a INSTITUTO DE PARASITOLOGÍA Y BIOMEDICINA LÓPEZ NEYRA   (Spain)

Author keywords

Cycloxygenase; Dendritic cells; Inflammation; Macrophages; Microglia; Neuropeptides; Prostaglandins

Indexed keywords

CYCLOOXYGENASE 2; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROSTAGLANDIN E2; VASOACTIVE INTESTINAL POLYPEPTIDE; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR; VASOACTIVE INTESTINAL POLYPEPTIDE RECEPTOR 1;

ANIMAL CELL; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CELL ACTIVATION; CONTROLLED STUDY; DEGENERATIVE DISEASE; DENDRITIC CELL; DOWN REGULATION; ENZYME INDUCTION; GENE ACTIVATION; INFLAMMATION; MACROPHAGE ACTIVATION; MICROGLIA; MOUSE; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROMOTER REGION; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; TRANSCRIPTION REGULATION;

ANIMALS; ANTI-INFLAMMATORY AGENTS; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE INHIBITORS; DENDRITIC CELLS; DINOPROSTONE; DOWN-REGULATION; DRUG SYNERGISM; GENE EXPRESSION; GENE EXPRESSION REGULATION; INFLAMMATION; INTERFERON TYPE II; LIPOPOLYSACCHARIDES; MACROPHAGES; MICE; MICE, INBRED BALB C; MICROGLIA; NF-KAPPA B; PROMOTER REGIONS (GENETICS); RECEPTORS, VASOACTIVE INTESTINAL POLYPEPTIDE, TYPE I; TRANS-ACTIVATION (GENETICS); VASOACTIVE INTESTINAL PEPTIDE;

EID: 36749079092     PISSN: 08891591     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbi.2007.07.004     Document Type: Article

References (39)

1. Abad C., Martinez C., Juarranz M.G., Arranz A., Receta J., Delgado M., and Gomariz R.P. Therapeutic effects of vasoactive intestinal peptide in the trinitrobenzene sulfonic acid mice model of Crohn's disease. Gastroenterology 124 (2003) 961-971
2. Brock T.G., McNish R.W., and Peters-Golden M. Arachidonic acid is preferentially metabolized by cyclooxygenase-2 to prostacyclin and prostaglandin E2. J. Biol. Chem. 274 (1999) 11660-11666
3. Chorny A., Gonzalez-Rey E., Varela N., Robledo G., and Delgado M. Signaling mechanisms of vasoactive intestinal peptide in inflammatory conditions. Regul. Pept. 137 (2006) 67-74
4. Crofford L.J., Tan B., McCarthy C.J., and Hla T. Involvement of NF-kB in the regulation of COX-2 expression by IL-1b in rheumatoid synoviocytes. Arthritis Rheum. 40 (1997) 226-236
5. Delgado M. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit CBP-NF-kappaB interaction in activated microglia. Biochem. Biophys. Res. Commun. 297 (2002) 1181-1185
6. Delgado M., Abad C., Martinez C., Leceta J., and Gomariz R.P. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease. Nat. Med. 7 (2001) 563-568
7. Delgado M., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit nuclear factor-kappa B-dependent gene activation at multiple levels in the human monocytic cell line THP-1. J. Biol. Chem. 276 (2001) 369-380
8. Delgado M., Gonzalez-Rey E., and Ganea D. The neuropeptide vasoactive intestinal peptide generates tolerogenic dendritic cells. J. Immunol. 175 (2005) 7311-7324
9. Delgado M., Jonakait G.M., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit chemokine production in activated microglia. Glia 39 (2002) 148-161
10. Delgado M., Leceta J., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit the production of inflammatory mediators by activated microglia. J. Leukoc. Biol. 73 (2003) 155-164
11. Delgado M., Munoz-Elias E.J., Gomariz R.P., and Ganea D. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide prevent inducible nitric oxide synthase transcription in macrophages by inhibiting NF-kappa B and IFN regulatory factor 1 activation. J. Immunol. 162 (1999) 4685-4696
12. Delgado M., Pozo D., Martinez C., Receta J., Calvo J.R., Ganea D., and Gomariz R.P. Vasoactive intestinal peptide and pituitary adenylate cyclase-activating polypeptide inhibit endotoxin-induced TNF-alpha production by macrophages: in vitro and in vivo studies. J. Immunol. 162 (1999) 2358-2367
13. Delgado M., Pozo D., and Ganea D. The significance of vasoactive intestinal peptide in immunomodulation. Pharmacol. Rev. 56 (2004) 249-290
14. Deng W.-G., Zhu Y., and Wu K.K. Role of p300 and PCAF in regulating cycloxygenase-2 promoter activation by inflammatory mediators. Blood 103 (2004) 2135-2142
15. Deng W.-G., Zhu Y., and Wu K.K. Up-regulation of p300 binding and p50 acetylation in tumor necrosis factor-alpha-induced cyclooxygenase-2 promoter activation. J. Biol. Chem. 278 (2003) 4770-4777
16. Fournier T., Fadok V., and Henson P.M. Tumor necrosis factor-a inversely regulates prostaglandin D2 and prostaglandin E2 production by murine macrophages. J. Biol. Chem. 272 (1997) 31065-31072
17. Gerritsen M.E., Williams A.J., Neish A.S., Moore S., Shi Y., and Collins T. CREB-binding protein/p300 are transcriptional coactivators of p65. Proc. Natl. Acad. Sci. USA 94 (1997) 2927-2932
18. Gonzalez-Rey E., Chorny A., and Delgado M. Regulation of immune tolerance by anti-inflammatory neuropeptides. Nat. Rev. Immunol. 7 (2007) 52-63
19. Gonzalez-Rey E., Varela N., Chorny A., and Delgado M. Therapeutical approaches of vasoactive intestinal peptide as a pleiotropic immunomodulator. Curr. Pharm. Des. 13 (2007) 1113-1139
20. Gonzalez-Rey E., and Delgado M. Vasoactive intestinal peptide and regulatory T-cell induction: a new mechanism and therapeutic potential for immune homeostasis. Trends Mol. Med. 13 (2007) 241-251
21. Gonzalez-Rey E., Fernandez-Martin A., Chorny A., Martin J., Pozo D., Ganea D., and Delgado M. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: downregulation of inflammatory and autoimmune responses. Am. J. Pathol. 168 (2006) 1179-1188
22. Gourlet P., De Neef P., Cnudde J., Waelbroeck M., and Robberecht P. In vitro properties of a high affinity selective antagonist of the VIP1 receptor. Peptides 18 (1997) 1555-1560
23. Gourlet P., Vandermeers A., Vertongen P., Ratche J., De Neef P., Cnudde J., Waelbroeck M., and Robberecht P. Development of high affinity selective VIP1 receptor agonists. Peptides 18 (1996) 1539-1545
24. Harris S.G., Padilla J., Koumas L., Ray D., and Phipps R.P. Prostaglandins as modulators of immunity. Trends Immunol. 23 (2002) 144-150
25. Herrera J.L., Fernandez-Montesinos R., Gonzalez-Rey E., Delgado M., and Pozo D. Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice. Ann. NY. Acad. Sci. 1070 (2006) 337-341
26. Iezzi A., Ferri C., Mezzetti A., and Cipollone F. COX-2: friend or foe?. Curr. Pharm. Des. 13 (2007) 1715-1721
27. Janknecht R., and Hunter T. Versatile molecular glue. Transcriptional control. Curr. Biol. 6 (1996) 951-954
28. Kalkhoven E. CBP and p300: HATs for different occasions. Biochem. Pharmacol. 68 (2004) 1145-1155
29. Karin M., and Greten F.R. NF-kappaB: linking inflammation and immunity to cancer development and progression. Nat. Rev. Immunol. 5 (2005) 749-759
30. Keino H., Kezuka T., Takeuchi M., Yamakawa N., Hattori T., and Usui M. Prevention of experimental autoimmune uveoretinitis by vasoactive intestinal peptide. Arch. Ophthalmol. 122 (2004) 1179-1184
31. Marnett L.J., and Kalgutkar A.S. Cyclooxygenase 2 inhibitors: discovery, selectivity and the future. Trends Pharmacol. Sci. 20 (1999) 465-469
32. Pozo D., and Delgado M. The many faces of VIP in neuroimmunology: a cytokine rather a neuropeptide?. FASEB J. 18 (2004) 1325-1334
33. Pozo, D., Gonzalez-Rey, E., Chorny, A., Anderson, P., Varela, N., Delgado M., in press. Tuning immune tolerance with vasoactive intestinal peptide: a new therapeutic approach for immune disorders. Peptides. doi:10.1016/j.peptides.2007.04.008.
34. Sheibanie A.F., Yen J.H., Khayrullina T., Emig F., Zhang M., Tuma R., and Ganea D. The proinflammatory effect of prostaglandin E2 in experimental inflammatory bowel disease is mediated through the IL-23 → IL-17 axis. J. Immunol. 178 (2007) 8138-8147
35. Subbaramaiah K., and Dannenberg A.J. Cyclooxygenase 2: a molecular target for cancer prevention and treatment. Trends Pharmacol. Sci. 24 (2003) 96-102
36. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97-120
37. Varela N., Chorny A., Gonzalez-Rey E., and Delgado M. Tuning inflammation with anti-inflammatory neuropeptides. Expert Opin. Biol. Ther. 7 (2007) 461-478
38. Wadleigh D.J., Reddy S.T., Kopp E., Ghosh S., and Herschman H.R. Transcriptional activation of the cyclooxygenase-2 gene in endotoxin-treated RAW264.7 macrophages. J. Biol. Chem. 275 (2000) 6259-6266
39. Xia M., Sreedharan S.P., Bolin D.R., Gaufo G.O., and Goetzl E.J. Novel cyclic peptide agonist of high potency and selectivity for the type II vasoactive intestinal peptide receptor. J. Pharmacol. Exp. Ther. 281 (1997) 629-633